Sexual Function in Postmenopausal Women With Symptomatic Pelvic Organ Prolapse Treated Either with Locally Applied Estrogen or Placebo: Results of a Double-Masked, Placebo-Controlled, Multicenter Trial.

Marie-Louise Marschalek, Klaus Bodner, Oliver Kimberger, Raffaela Morgenbesser, Wolf Dietrich, Christian Obruca, Heinrich Husslein, Wolfgang Umek, Heinz Koelbl, Barbara Bodner-Adler

Journal: The journal of sexual medicine 2022;19(7):1124-1130

PMID: 35610142

Abstract

BACKGROUND

Local estrogen therapy (LET) has beneficial effects on genitourinary atrophy; however it is currently unclear if LET improves sexual function in postmenopausal women with pelvic organ prolapse (POP).

AIM

To evaluate if LET vs placebo results in an improved sexual function in postmenopausal women with symptomatic POP.

METHODS

We performed a secondary analysis of sexual outcomes of a previous randomized controlled trial comparing LET and placebo in 120 postmenopausal women (60/group) with symptomatic POP stage ≥3 and planned prolapse surgery. Women were randomly assigned to receive local estrogen or placebo cream 6 weeks preoperatively. The effect of therapy vs placebo was assessed with ANOVA with interaction effect of time*group and a multivariable linear regression model was built to assess the impact of different variables on sexual function before therapy.

OUTCOMES

We evaluated the sexual function score in sexually active women of our study population using the German Pelvic Floor Questionnaire at recruitment time and again after 6 weeks of treatment.

RESULTS

Among 120 randomized women, 66 sexually active women remained for final analysis. There was no significant difference in the change of the sexual function score over time between the treatment groups (difference in changes in score from baseline to 6 weeks for Estrogen group vs control group was -0.110 with 95% CI -0.364 to 0.144) Multivariable analysis showed that no independent risk factor for unsatisfying sexual function score could be identified.

CLINICAL IMPLICATIONS

Based on our results, LET has no beneficial effect on sexual function in postmenopausal women with POP.

STRENGTHS AND LIMITATIONS

Main strength of our study lies in the study design and in the use of a condition- specific questionnaire. As this is a secondary analysis, this study may be insufficiently powered to identify differences in sexual data between groups.

CONCLUSION

LET had no impact on female sexuality in postmenopausal women with POP. Marschalek M-L, Bodner K, Kimberger O, et al. Sexual Function in Postmenopausal Women With Symptomatic Pelvic Organ Prolapse Treated Either with Locally Applied Estrogen or Placebo: Results of a Double-Masked, Placebo-Controlled, Multicenter Trial. J Sex Med 2022;19:1124-1130.

Copyright © 2022 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Address: Department of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Vienna, Austria.; Department of Anesthesiology, Medical University of Vienna, Vienna, Austria.; Karl Landsteiner University of Health Sciences, Department of Gynecology and Obstetrics, University Hospital Tulln, Vienna, Austria.; Department of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute, Department of Special Gynecology and Obstetrics, Vienna, Austria.; Department of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute, Department of Special Gynecology and Obstetrics, Vienna, Austria. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.